J&J's IBD combo fails Phase 2 studies, but will move into pivotal testing

May 5, 2026 10:30 AM EDT R&D J&J's IBD com­bo fails Phase 2 stud­ies, but will move in­to piv­otal test­ing Max Gelman Senior Editor John­son & John­son will move a treat­ment for in­flam­ma­to­ry bow­el dis­ease in­to Phase 3 stud­ies de­spite the ther­a­py’s fail­ure in two mid-stage tri­als. The com­pa­ny … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER